文档介绍：Incorporating Molecular Data into Risk Stratification for AML
Steven Devine .
The Ohio State prehensive Cancer Center
About These Slides
Our thanks to the presenters who gave permission to include their original data
Users are encouraged to use these slides in their own mercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent
These slides may not be published or posted online without permission from Clinical Care Options
DisclaimerThe materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or panies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Current State of AML Therapy
Excluding the roughly 20-30% of good risk patients, 40-90% of younger patients (age 18-59) achieving remission are destined to relapse
Current State of AML Therapy
Excluding the roughly 20-30% of good risk patients, 40-90% of younger patients (age 18-59) achieving remission are destined to relapse
All but a very select subset of older AML patients (> 60) will die due to relapsed or refractory disease
Prognostic/predictive factors in AML
Factor
Comment
Age
Major impact at diagnosis
WBC
Continuous variable
Prior therapy or MDS?
Karyotype may be more important
Extramedullary disease
Variable
Day 14 blast count
Higher percentage worse
# cycles of induction
One better than two
ic/molecular profile
Major Impact at diagnosis
Gene expression profile
Can further subdivide patients
MicroRNA expression
Needs validation by other groups
Gene sequenci